<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02527200</url>
  </required_header>
  <id_info>
    <org_study_id>NN8022-4179</org_study_id>
    <secondary_id>2014-004415-37</secondary_id>
    <secondary_id>U1111-1162-7884</secondary_id>
    <secondary_id>NL54145.078.15</secondary_id>
    <nct_id>NCT02527200</nct_id>
  </id_info>
  <brief_title>Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome</brief_title>
  <official_title>Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted globally. The aim of this trial is to investigate the effect of&#xD;
      liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 2015</start_date>
  <completion_date type="Actual">November 19, 2020</completion_date>
  <primary_completion_date type="Actual">November 4, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body mass index (BMI) standard deviation score (SDS)</measure>
    <time_frame>Week 0, Week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in body mass index (BMI) standard deviation score (SDS)</measure>
    <time_frame>Week 0, Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects achieving equal to or above 5% reduction in baseline BMI</measure>
    <time_frame>At weeks 16 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects achieving equal or above 10% reduction in baseline BMI</measure>
    <time_frame>At weeks 16 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body mass index (BMI)</measure>
    <time_frame>Week 0, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body mass index (BMI)</measure>
    <time_frame>Week 0, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight (kilogram (kg), pounds (lb) and percent (%))</measure>
    <time_frame>Week 0, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight (kilogram (kg), pounds (lb) and percent (%))</measure>
    <time_frame>Week 0, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperphagia total score</measure>
    <time_frame>Week 0, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperphagia total score</measure>
    <time_frame>Week 0, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hyperphagic behaviour score</measure>
    <time_frame>Week 0, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hyperphagic behaviour score</measure>
    <time_frame>Week 0, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperphagia drive score</measure>
    <time_frame>Week 0, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperphagia drive score</measure>
    <time_frame>Week 0, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperphagia severity score</measure>
    <time_frame>Week 0, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperphagia severity score</measure>
    <time_frame>Week 0, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic and diastolic blood pressure</measure>
    <time_frame>Week 0, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic and diastolic blood pressure</measure>
    <time_frame>Week 0, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycosylated Haemoglobin (HbA1c)</measure>
    <time_frame>Week 0, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycosylated Haemoglobin (HbA1c)</measure>
    <time_frame>Week 0, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG)</measure>
    <time_frame>Week 0, Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG)</measure>
    <time_frame>Week 0, Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Metabolism and Nutrition Disorder</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.</description>
    <arm_group_label>Liraglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained before any trial-related activities. Trial-related&#xD;
             activities are any procedures that are carried out as part of the trial, including&#xD;
             activities to determine suitability for the trial&#xD;
&#xD;
          -  Confirmed diagnosis of PWS (Prader-Willi Syndrome) (by genetic testing)&#xD;
&#xD;
          -  Male or female, age at the time of signing informed consent: - Part A: above or equal&#xD;
             to 12 years and less than 18 years&#xD;
&#xD;
          -  Tanner stage 2-5 pubertal development for part A, and Tanner stage 1 for part B&#xD;
&#xD;
          -  BMI (body mass index) corresponding to equal or above 30 kg/m^2 for adults by&#xD;
             international cut-off points1 and equal or above the 95th percentile for age and sex&#xD;
             (for diagnosis of obesity)&#xD;
&#xD;
          -  Stable body weight during the previous 90 days before screening ( below 10 kg&#xD;
             self-reported weight change)&#xD;
&#xD;
          -  Testing has been performed to evaluate for adrenal insufficiency and documented in&#xD;
             medical record&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus (T1DM)&#xD;
&#xD;
          -  Type 2 diabetes mellitus (T2DM)&#xD;
&#xD;
          -  Calcitonin equal or above 50 ng/L&#xD;
&#xD;
          -  No change in treatment plan with growth hormone (GH) from randomisation to the end of&#xD;
             the open-label period patients on growth hormone to stay on, patients off GH to stay&#xD;
             off during this period. Adjustments in doses of growth hormone will be permitted)&#xD;
&#xD;
          -  Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN2) or Medullary&#xD;
             Thyroids Carcinoma (MTC)&#xD;
&#xD;
          -  History of pancreatitis (acute or chronic)&#xD;
&#xD;
          -  Treatment with any medication prescribed for weight loss within 90 days before&#xD;
             screening (e.g. orlistat, zonisamide, topiramate/phentermine, lorcaserin, phentermine,&#xD;
             bupropion/naltrexone,liraglutide, metformin)&#xD;
&#xD;
          -  Untreated adrenal insufficiency&#xD;
&#xD;
          -  Suggestive history of, or significant risk of gastroparesis (e.g. marked abdominal&#xD;
             bloating post meal, history of vomiting, severe constipation), as judged by the&#xD;
             Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>ANGERS cedex 09</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>BRON cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Haguenau</city>
        <zip>67504</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>MARSEILLE CÃ©dex 05</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>MONTPELLIER cedex 05</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fiumicino</city>
        <zip>00050</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Grafton</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06010</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34890</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2015</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <pending_results>
    <submitted>October 27, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

